Koers Allarity Therapeutics, Inc. Nasdaq Stockholm
Aandelen
ALLR
US0167441049
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 423K 4,6 mln. 395K |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -174 mln. -14,92 mln. | Nettowinst (verlies) 2025 * | -28 mln. -304 mln. -26,11 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,05
x | K/w-verhouding 2025 * |
-0,05
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 12,94% |
Recentste transcriptie over Allarity Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Jensen
FOU | Founder | 46 | 01-06-20 |
Joan Brown
DFI | Director of Finance/CFO | 71 | 21-09-21 |
Chief Tech/Sci/R&D Officer | 63 | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 56 | 01-10-22 | |
Thomas Jensen
FOU | Founder | 46 | 01-06-20 |
Joseph Vazzano
BRD | Director/Board Member | 40 | 01-08-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,65% | 104 mld. | |
+6,75% | 97,47 mld. | |
+5,71% | 22,25 mld. | |
-12,60% | 21,68 mld. | |
-9,70% | 18,2 mld. | |
-39,98% | 17,02 mld. | |
-10,17% | 16,36 mld. | |
+6,12% | 14,39 mld. | |
+35,47% | 12,37 mld. |